NCT03348709

Brief Summary

This double-blinded, active comparator, cross-over intervention study tested the impact of two different oral supplements on ileostomy output volume and urinary sodium excretion and intestinal aquaporin expression in eight compensated patients with an ileostomy and not on home parenteral Nutrition or fluid support.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 16, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 21, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2018

Completed
Last Updated

November 5, 2018

Status Verified

November 1, 2018

Enrollment Period

1 year

First QC Date

November 16, 2017

Last Update Submit

November 2, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Stoma output

    24 hour stoma output weight

    24 hours

Secondary Outcomes (2)

  • 24-hour urine production

    24 hours

  • 24-hour urinary sodium excretion

    24 hours

Study Arms (2)

Isoosmolar

EXPERIMENTAL

Iso-osmolar oral supplement (276 mOsm/kg)

Dietary Supplement: Isoosmolar

Hyperosmolar

ACTIVE COMPARATOR

Hyper-osmolar oral supplement (681 mOsm/kg)

Dietary Supplement: Hyperosmolar

Interventions

IsoosmolarDIETARY_SUPPLEMENT

48 hours, 800 ml per 24 hours

Isoosmolar
HyperosmolarDIETARY_SUPPLEMENT

48 hours, 800 ml per 24 hours

Hyperosmolar

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 18 years or more
  • able to drink at least 100 ml fluid per 24 hours
  • i known inflammatory bowel disease, clinical remission judged by physician's global assessment (PGA)
  • less than 5 kg self-reported weight change during the past 3 months

You may not qualify if:

  • self-reported intolerance to dairy products, including lactose
  • known renal insufficiency, defined by an eGFR less than 30 ml/min
  • known diabetes mellitus, defined by an HbA1C \> 48 mmol/mol (6.5%)
  • current enteral tube feeding or parenteral fluid or Nutrition support more than twice weekly

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aarhus University Hospital

Aarhus C, 8000, Denmark

Location

Related Publications (1)

  • Rud C, Pedersen AKN, Wilkens TL, Borre M, Andersen JR, Moeller HB, Dahlerup JF, Hvas CL. An iso-osmolar oral supplement increases natriuresis and does not increase stomal output in patients with an ileostomy: A randomised, double-blinded, active comparator, crossover intervention study. Clin Nutr. 2019 Oct;38(5):2079-2086. doi: 10.1016/j.clnu.2018.10.014. Epub 2018 Oct 24.

MeSH Terms

Conditions

Short Bowel SyndromeHyponatremiaMalnutrition

Condition Hierarchy (Ancestors)

Malabsorption SyndromesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsWater-Electrolyte ImbalanceMetabolic DiseasesNutritional and Metabolic DiseasesNutrition Disorders

Study Officials

  • Hendrik Vilstrup, Professor

    University of Aarhus

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Randomisation by Third party; Unblinded study nurse to mix and deliver study product; masking of product to ensure comparable palatability and appearance; blinding to analyses
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Double-blinded, active comparator, cross-over intervention study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD PhD, associate professor

Study Record Dates

First Submitted

November 16, 2017

First Posted

November 21, 2017

Study Start

June 1, 2017

Primary Completion

June 1, 2018

Study Completion

November 1, 2018

Last Updated

November 5, 2018

Record last verified: 2018-11

Data Sharing

IPD Sharing
Will share

Publication of anonymised data. Data backup in accessible data platform.

Shared Documents
STUDY PROTOCOL, ICF, CSR
Time Frame
During last 6 months of study period, 10 years
Access Criteria
established researcher

Locations